Wealth Enhancement Advisory Services
REGN icon

Wealth Enhancement Advisory Services’s Regeneron Pharmaceuticals REGN Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-900
Closed -$71.1K – 3086
2024
Q3 		$71.1K Buy
+900
New +$1M ﹤0.01% 2595

Other funds holding REGN

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
VF
Vest Financial Mclean, Virginia $9.52B AUM 31.6% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

Wealth Enhancement Advisory Services's REGN Position: Q2 2026 in Review

Wealth Enhancement Advisory Services reduced its Regeneron Pharmaceuticals (REGN) stake by 9.9% in Q2 2026, selling an estimated $2.53M and leaving 33,880 shares worth $15.9M. The position accounts for 0.03% of the portfolio, ranked #509.

Wealth Enhancement Advisory Services first reported a position in REGN in Q3 2016 and has held it in 20 quarters since. The position peaked at $32.8M in Q4 2024. 349 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Wealth Enhancement Advisory Services held 33,880 shares of Regeneron Pharmaceuticals worth $15.9M as of Q2 2026.
  • Wealth Enhancement Advisory Services sold 3,716 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $2.53M.
  • Regeneron Pharmaceuticals made up 0.03% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #509 holding.
  • Wealth Enhancement Advisory Services first reported a position in Regeneron Pharmaceuticals in Q3 2016 and has held it in 20 quarters since.
  • Wealth Enhancement Advisory Services's Regeneron Pharmaceuticals position peaked at $32.8M in Q4 2024.
  • 349 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.